MYOSTATIN AS A POTENTIAL DIAGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH SARCOPENIA | ||
| NILES journal for Geriatric and Gerontology | ||
| Article 2, Volume 7, Issue 2, July 2024, Pages 321-339 PDF (391.28 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/niles.2024.275569.1081 | ||
| Authors | ||
| marwa saad* 1; Sekina Ahmed2; Mahmoud Abdelmajeed3; Reham Aboelwafa4; Doaa Mounir Mahmoud Genena5; Rana Emara6 | ||
| 1professor of internal medicine, Geriatric unite, Internal Medicine department, faculty of medicine , Alexandria university | ||
| 2Geriatric unit, Internal Medicine Department, Faculty of Medicine, Alexandria university, | ||
| 3Internal medicine department, General Navy Hospital | ||
| 4clinical and chemical pathology, Faculty of medicine, Alexandria university | ||
| 5Department of nutrition and public health,Institute of Medical Research, Alexandria University, Egypt | ||
| 6Lecturer of Nutrition, High Institute of Public Health, Faculty of Medicine, Alexandria university | ||
| Abstract | ||
| Sarcopenia is a progressive loss of skeletal muscle mass and strength. Myostatin is a myokine, and a potent negative regulator of muscle growth. This study aimed to assess the accuracy of serum myostatin in prediction of Sarcopenia in elderly patients and correlate it with QoL. The study involved 64 elderly patients aged 65 years and older; Group (I):32 sarcopenic patients, and Group (II):32 healthy age and sex-matched control participants. Participants with chronic renal, hepatic, or cardiac compensation, DM, women on hormonal replacement therapy were excluded. All participants were subjected to history taking, clinical examination, anthropocentric measurements, routine laboratory investigations, serum myostatin using ELISA, and SF-36 to assess QoL. Sarcopenia was diagnosed using EWGSOP-2 criteria. Sarcopenic patients had significantly lower ASMI, hand grip strength, and physical performance values (p<0.001). Serum Myostatin level in sarcopenic patients was significantly higher compared to controls (32.73 ± 5.0 vs. 26.49 ± 6.44 IU/dl) (p<0.001). Sarcopenic patients had significantly lower scores of SF-36 score compared to the controls (74.19 ± 5.04 vs 84.84 ± 3.33) (p<0.001).A significant negative correlation was found between serum myostatin and SF-36 scores in the sarcopenic group compared to the control group (r= -0.345; p<0.001).Serum myostatin level more than 29 (IU/dl) has sensitivity of (87.5%) and specificity of (75%) in discriminating sarcopenic patients from healthy elders. In conclusion; serum myostatin is a possible blood-based biomarker for Sarcopenia prediction as well as quality of life assessment in such population. Further researches with more sample sizes are required to confirm our outcomes. | ||
| Keywords | ||
| loss of muscle mass and function; quality of life; elders; negative regulators of skeletal muscles | ||
|
Statistics Article View: 280 PDF Download: 240 |
||
